Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.
Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, Perez A, Sardo D, Inguglia S, Iacono F, Cutaia S, Bazan Russo TD, Francini E, Incorvaia L, Badalamenti G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: francini e. Cancers (Basel). 2022 Dec 6;14(23):6013. doi: 10.3390/cancers14236013. Cancers (Basel). 2022. PMID: 36497493 Free PMC article.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G; Multidisciplinary Oncology Group in Gastrointestinal Tumors. Petrioli R, et al. Among authors: francini g, francini e. Anticancer Drugs. 2010 Mar;21(3):313-9. doi: 10.1097/CAD.0b013e328334d88a. Anticancer Drugs. 2010. PMID: 20016369 Clinical Trial.
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G; Multidisciplinary Oncology Group on Gastrointestinal Tumors. Petrioli R, et al. Among authors: francini g, francini e. Anticancer Drugs. 2008 Jan;19(1):91-6. doi: 10.1097/CAD.0b013e3282f21363. Anticancer Drugs. 2008. PMID: 18043134
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Petrioli R, et al. Among authors: francini g, francini e. Br J Cancer. 2011 Feb 15;104(4):613-9. doi: 10.1038/bjc.2011.5. Epub 2011 Feb 1. Br J Cancer. 2011. PMID: 21285986 Free PMC article. Clinical Trial.
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.
Rossi L, Tomao F, Lo Russo G, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S. Rossi L, et al. Among authors: francini e. Ther Clin Risk Manag. 2013;9:457-62. doi: 10.2147/TCRM.S48387. Epub 2013 Nov 11. Ther Clin Risk Manag. 2013. PMID: 24255599 Free PMC article.
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Wagner AD, et al. Among authors: francini e. J Natl Cancer Inst. 2021 Apr 6;113(4):400-407. doi: 10.1093/jnci/djaa124. J Natl Cancer Inst. 2021. PMID: 32835356 Free PMC article.
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA. Moreira RB, et al. Among authors: francini e. Oncotarget. 2017 Aug 8;8(48):84572-84578. doi: 10.18632/oncotarget.20028. eCollection 2017 Oct 13. Oncotarget. 2017. PMID: 29137449 Free PMC article. Review.
89 results